The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients. But, oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
